ACP
TSHA icon

Acuta Capital Partners’s Taysha Gene Therapies TSHA Stock Holding History

Acuta Capital Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Buy
561,808
+122,344
+28% +$724K 2.67% 15
2026
Q1 		$1.96M Sell
439,464
-15,363
-3% -$71.4K 1.39% 18
2025
Q4 		$2.5M Hold
454,827
– – 1.7% 15
2025
Q3 		$1.49M Sell
454,827
-30,842
-6% -$87.3K 1.54% 17
2025
Q2 		$1.12M Buy
+485,669
New +$1.06M 1.57% 18
2025
Q1 		– Sell
-884,244
Closed -$1.53M – 44
2024
Q4 		$1.53M Sell
884,244
-1,234,748
-58% -$2.56M 1.54% 22
2024
Q3 		$4.26M Sell
2,118,992
-211,945
-9% -$465K 3.45% 10
2024
Q2 		$5.22M Sell
2,330,937
-1,002,396
-30% -$2.92M 4.4% 8
2024
Q1 		$9.57M Sell
3,333,333
-256,000
-7% -$533K 6.21% 4
2023
Q4 		$6.35M Sell
3,589,333
-238,593
-6% -$476K 3.58% 10
2023
Q3 		$12.1M Buy
+3,827,926
New +$7.15M 8.11% 1

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acuta Capital Partners's TSHA Position: Q2 2026 in Review

Acuta Capital Partners increased its Taysha Gene Therapies (TSHA) stake by 28% in Q2 2026, buying an estimated $724K and bringing the position to 561,808 shares worth $3.83M. The position accounts for 2.67% of the portfolio, ranked #15.

Acuta Capital Partners first reported a position in TSHA in Q3 2023 and has held it in 11 quarters since. The position peaked at $12.1M in Q3 2023. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Acuta Capital Partners held 561,808 shares of Taysha Gene Therapies worth $3.83M as of Q2 2026.
  • Acuta Capital Partners bought 122,344 Taysha Gene Therapies shares in Q2 2026, an estimated $724K.
  • Taysha Gene Therapies made up 2.67% of Acuta Capital Partners's portfolio in Q2 2026, its #15 holding.
  • Acuta Capital Partners first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 11 quarters since.
  • Acuta Capital Partners's Taysha Gene Therapies position peaked at $12.1M in Q3 2023.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.